SeniorJournal.com - Daily News for Senior Citizens

  FRONT PAGE Aging • Health • Alzheimer's - Mental • Nutrition • Medicare & Medicaid Politics  • Fitness  • Social Security • Alerts • Sex Health • Features • Retirement  Elder Care  >Search  >Senior Links

[NavBar.htm]

Senior Journal: Today's News and Information for Senior Citizens & Baby Boomers

More Senior Citizen News and Information Than Any Other Source - SeniorJournal.com

• Go to more on Health & Medicine or More Senior News from SeniorJournal.com on the Front Page

   

E-mail this page to a friend!

Health & Medicine for Senior Citizens

Follow-Up to Estrogen Therapy Trial Finds Reduced Risk of Breast Cancer, But...

Younger women achieved better health gains than older women - 'need to counsel women about hormone therapy differently depending on their age'

Click to video on study

April 6, 2011 - Among postmenopausal women with a prior hysterectomy and who had used estrogen therapy for about 6 years and then stopped, longer-term follow-up indicates that the risk of breast cancer was reduced, regardless of age. Health outcomes were, however, more favorable for younger compared with older women for CHD, heart attack, colorectal cancer, total mortality, and a global index of chronic diseases.

Generally, however, the report in the April 6 issue of the Journal of the American Medical Association (JAMA) finds the increased risk of stroke seen during the therapy intervention period had dissipated, the decreased risk of hip fracture was not maintained.

"The Women's Health Initiative (WHI) Estrogen-Alone Trial was a double-blind, placebo-controlled, randomized clinical trial evaluating the effects of conjugated equine estrogens (CEE) on chronic disease incidence among postmenopausal women with prior hysterectomy," the authors write.

The trial intervention was stopped 1 year early after an average of 7.1 years of follow-up because of an increased risk of stroke and little likelihood of altering the balance of risk to benefit by the planned termination date. All previous reports of this trial were limited to health outcomes occurring during the intervention phase, according to background information in the article.

Researchers led by Andrea Z. LaCroix, Ph.D., of the Fred Hutchinson Cancer Research Center, Seattle, analyzed data on health outcomes after the CEE intervention through an average of 10.7 years of follow-up, through August 2009.

The intervention phase was a clinical trial of 0.625 mg/d of CEE compared with placebo in 10,739 U.S. postmenopausal women, ages 50 to 79 years with prior hysterectomy. Follow-up continued after the planned trial completion date among 7,645 surviving participants (78 percent) who provided written consent.

 

Related Archive Stories

 
 

Postmenopausal Women Treated with Hormone Therapy Suffer More Deadly Breast Cancers

JAMA editorial says, ‘the available data dictate caution in the current approach to use of hormone therapy’

Oct. 20, 2010

Cancer Rates Continue to Decline Despite Booming Senior Citizen Population

First ever decrease in death from lung cancer for women; men see small increase in prostate cancer rate

April 1, 2011

Senior Women Who Survive Breast Cancer Have a Greater Risk of Falling

Cancer therapies may affect balance, says new study in Archives of Physical Medicine and Rehabilitation

March 10, 2011

CDC Releases 34th Annual Report on the Nation’s Health; Feature Section on Dying

Data from state and federal health agencies as well as an in-depth feature section on death and dying

Feb. 16, 2011


 
 

Read the latest news
> Health & Medicine
>
Today's Headlines

 

The researchers found that the risk for coronary heart disease (CHD) during the post-intervention follow-up period was similar to that observed during the intervention.

The increased stroke risk seen during the intervention phase was not present during the post-intervention phase (0.36% for 66 women) in the CEE group vs. 0.41 percent (77 women)] in the placebo group.

Similarly, the increase in deep vein thrombosis and pulmonary embolism with CEE use compared with placebo during the intervention phase was not maintained during the post-intervention phase.

The risk of invasive breast cancer in women randomized to CEE vs. placebo was similar during the intervention and post-intervention phases. "Consequently, a statistically significant lower cumulative breast cancer incidence of 0.27 percent was seen in the CEE group (n = 151) compared with 0.35 percent in the placebo group (n=199).

Colorectal cancer incidence did not differ between the women in the CEE group and the placebo group during the intervention or post-intervention periods," the authors write.

They add that the reduced hip fracture risk seen during the intervention phase with CEE was not maintained in the post-intervention phase, with hip fracture incidence slightly higher in the CEE group compared with the placebo group during the post-intervention phase. Randomization to CEE did not influence total mortality during the intervention or post-intervention phase.

Health outcomes were more favorable for younger compared with older women for CHD, heart attack, colorectal cancer, total mortality, and a global index of chronic diseases.

"Our results emphasize the need to counsel women about hormone therapy differently depending on their age and hysterectomy status,” wrote the researchers.

“A postmenopausal woman who has had a hysterectomy and is considering initiation of CEE should be counseled about the increased risks of venous thromboembolism and a stroke during treatment, which diminish with treatment cessation.

“Among younger women, no new safety concerns emerged and some risk reductions became apparent during the post-intervention period.

“Among older women, risks of colorectal cancer, death, and the global index of chronic diseases were elevated over the cumulative follow-up period.

“The risks and benefits of CEE use for periods of longer than 5 to 6 years cannot be inferred from these data for any age group. Mechanisms underlying the reduced risks of breast cancer in all women, and coronary events in younger but not older women, warrant further study," the authors conclude.

Editorial: Short-term Use of Unopposed Estrogen - A Balance of Inferred Risks and Benefits

In an accompanying editorial, Emily S. Jungheim, M.D., M.S.C.I., and Graham A. Colditz, M.D., Dr.P.H., of the Washington University School of Medicine, St. Louis, write that findings from the WHI have been an important guide for clinicians on the overall risks and benefits of hormone therapy (HT).

"There may still be a role for short-term use of unopposed estrogen for treating some women with menopausal symptoms, but this role may be vanishing as existing and emerging data continue to be better understood in terms of application to patients,” according to an accompanying editorial by Emily S. Jungheim, M.D., M.S.C.I., and Graham A. Colditz, M.D., Dr.P.H., of the Washington University School of Medicine, St. Louis.

“Findings from the WHI have been an important guide for clinicians on the overall risks and benefits of hormone therapy (HT),” they add.

“In the meantime, the symptoms of menopause can be significant and require thoughtful management. This would include careful consideration and discussion of the long-term risks and short-term benefits of HT as well as thorough discussion of other treatment strategies and optimization of lifestyle to ensure the best outcomes for women in the many years they should enjoy post-menopause."

> Medical Malpractice,

> Nursing Home Abuse,

> Personal Injury

Our Experienced Lawyers Can Help

Beth Janicek, Board Certified Personal Injury Attorney"We win because we care, we prepare and we have no fear," Beth Janicek, board certified personal injury attorney

 

Free Consultation on your case.

Call Now Toll Free

1-877-795-3425

or Send Email

More at our Website

 

 

Search for more about this topic on SeniorJournal.com

Google Web SeniorJournal.com

Keep up with the latest news for senior citizens, baby boomers

 

Click to More Senior News on the Front Page

Copyright: SeniorJournal.com

    

 

Published by New Tech Media - www.NewTechMedia.com

Other New Tech Media sites include CaroleSutherland.com, BethJanicek.com, SASeniors.com, DrugDanger.com, etc.